

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/587,569
Filing Date	July 31, 2006
First Named Inventor	CAPPOLA, Thomas
Art Unit	1631
Examiner Name	Not yet known
Attorney Docket Number	P-7627-US

Sheet

1

of

4

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A	US-2004/0009479	Jan. 15, 2004	Wohlgemuth, et al	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	B	WO 9915700	04/01/1999			<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/587,569
				Filing Date	July 31, 2006
				First Named Inventor	CAPPOLA, Thomas
				Art Unit	1631
				Examiner Name	Not yet known
Sheet	2	of	4	Attorney Docket Number	P-7627-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C	Billingham ME. et al "A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group". The International Society for Heart Transplantation. J Heart Transplant. 1990;9:587-93	<input type="checkbox"/>
	D	Pophal SG. et al "Complications of endomyocardial biopsy in children" J Am Coll Cardiol. 1999;34:2105-10.	<input type="checkbox"/>
	E	de Groot-Kruseman HA et al, "Intragraft interleukin 2 mRNA expression during acute cellular rejection and left ventricular total wall thickness after heart transplantation". Heart. 2002;87:363-7.	<input type="checkbox"/>
	F	Shulzhenko N. et al "Monitoring of intragraft and peripheral blood TIRC7 expression as a diagnostic tool for acute cardiac rejection in humans". Hum Immunol. 2001;62:342-7.	<input type="checkbox"/>
	G	Shulzhenko N. et al "Intragraft activation of genes encoding cytotoxic T lymphocyte effector molecules precedes the histological evidence of rejection in human cardiac transplantation". Transplantation. 2001;72:1705-8.	<input type="checkbox"/>
	H	Shulzhenko N, et al "Expression of CD40 ligand, interferon-gamma and Fas ligand genes in endomyocardial biopsies of human cardiac allografts: correlation with acute rejection". Braz J Med Biol Res. 2001;34:779-84.	<input type="checkbox"/>
	I	van Emmerik N. et al "Cytokine gene expression profiles in human endomyocardial biopsy (EMB) derived lymphocyte cultures and in EMB tissue". Transpl Int. 1994;7 Suppl 1:S623-6.	<input type="checkbox"/>
	JK	Alpert S, Lewis NP et al "The relationship of granzyme A and perforin expression to cardiac allograft rejection and dysfunction". Transplantation. 1995;60:1478-85.	<input type="checkbox"/>
	K	Baan CC et al "Cytokine mRNA expression in endomyocardial biopsies during acute rejection from human heart transplants". Clin Exp Immunol. 1994;97:293-8.	<input type="checkbox"/>
	L	Kobashigawa JA. "Treatment of nonhemodynamic compromising rejection: conventional approaches vs individualization/new immunosuppressive drugs". Transplant Proc. 1997;29:37S-39S.	<input type="checkbox"/>
			<input type="checkbox"/>


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/587,569
				Filing Date	July 31, 2006
				First Named Inventor	CAPPOLA, Thomas
				Art Unit	1631
				Examiner Name	Not yet known
Sheet	3	of	4	Attorney Docket Number P-7627-US	

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	M	Li C, et al. "Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection". 2001;98:31-36.	<input type="checkbox"/>
	N	Seo J, et al. "Optimizing signal/noise ratios in expression profiling: project-specific algorithm selection and detection p value weighting in affymetrix microarrays". Bioinformatics. 2004.	<input type="checkbox"/>
	O	Irizarry RA, et al "Speed TP. Exploration, Normalization, and Summaries of High Density Oligonucleotide Array Probe Level Data Biostatistics". 2003;4:249-264.	<input type="checkbox"/>
	P	Wu Z, et al "Preprocessing of oligonucleotide array data". Nat Biotechnol. 2004;22:656-8.	<input type="checkbox"/>
	Q	Ihaka R et al "A Language for Data Analysis and Graphics. Journal of Graphical and Computational Statistics". 1996;5:299-314.	<input type="checkbox"/>
	R	Tusher VG et al "Significance analysis of microarrays applied to the ionizing radiation response". Proc Natl Acad Sci U S A. 2001;98:5116-21.	<input type="checkbox"/>
	S	Eisen MB et al "Cluster analysis and display of genome-wide expression patterns". 1998;95:14863-14868.	<input type="checkbox"/>
	T	Kimball PM et al "The paradox of cytokine monitoring-predictor of immunologic activity as well as immunologic silence following cardiac transplantation". Transplantation. 1996;61:909-15.	<input type="checkbox"/>
	U	Lagoo AS et al, "Semiquantitative measurement of cytokine messenger RNA in endomyocardium and peripheral blood mononuclear cells from human heart transplant recipients". Journal of Heart & Lung Transplantation. 1996;15:206-17.	<input type="checkbox"/>
	V	Morgun A et al "Cytokine and TIRC7 mRNA expression during acute rejection in cardiac allograft recipients". Transplant Proc. 2001;33:1610-1.	<input type="checkbox"/>
	W	Valk PJ et al "Prognostically useful gene-expression profiles in acute myeloid leukemia". N Engl J Med. 2004;350:1617-28.	<input type="checkbox"/>
	X	Bullinger L et al "Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia". N Engl J Med. 2004;350:1605-16.	<input type="checkbox"/>


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/587,569
				Filing Date	July 31, 2006
				First Named Inventor	CAPPOLA, Thomas
				Art Unit	1631
				Examiner Name	Not yet known
Sheet	4	of	4	Attorney Docket Number	P-7627-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	Y	Rosenwald A et al, "The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma". N Engl J Med. 2002;346:1937-47.	<input type="checkbox"/>
	Z	Sarwal M et al, "Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling". N Engl J Med. 2003;349:125-38.	<input type="checkbox"/>
	a	Inohara N et al, "CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis". Proc Natl Acad Sci U S A. 1997;94:10717-22.	<input type="checkbox"/>
	b	Expression profiling--best practices for data generation and interpretation in clinical trials. The Tumor Analysis Best Practices Working Group. Nat Rev Genet. 2004;5:229-37.	<input type="checkbox"/>
	c	Baechler EC et al, "Expression levels for many genes in human peripheral blood cells are highly sensitive to ex vivo incubation". Genes Immun. 2004.	<input type="checkbox"/>
	d	Guerette B et al "Increased granzyme B mRNA after alloincompatible myoblast transplantation" Transplantation, Williams and Wilkins, Baltimore, MD US., vol. 60, no. 9, Nov 15, 1995 (pages 1011-1016	<input type="checkbox"/>
	e	Tewari, M. et al "Lymphoid expression and regulation of A20, an inhibitor of programmed cell death" J. Immunol., vo. 154, No. 4 1995, pages 1699-1706	<input type="checkbox"/>
	f	Clement, M.V. et al "Perforin and granzyme B expression is associated with severe acute rejection" Transplantation, vol., 57 no. 3, 1994, pages 322-326	<input type="checkbox"/>
	g	Strehlau J., et al "Quantificative detection of immune activation transcripts as a diagnostic tool in kidney transplantation" Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, US, vol. 94, 1997, pages 695-700	<input type="checkbox"/>
	h	Griffiths G M et al "Granzyme A and perforin as markers for rejection in cardiac transplantation: European Journal of Immunology, Weinheim, de, vol. 21, 1991, pages 687-692	<input type="checkbox"/>
	i	Lipman M.L. et al "Heightened intragraft cytotoxic T lymphocyte gene expression in acutely rejecting renal allografts" J. Immunol., vol. 152, 1994, pages 5120-5127	
	j	Soares, M.P. et al "Expression of heme oxygenase-1 can determine cardiac xenograft survival" Mat. Med., vol., 4, no. 9, September 1998, pages 1073-1077	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.